AMADIS
28.3.2022 07:02:12 CEST | Business Wire | Press release
PayPlug (part of the Payment activities of Groupe BPCE ) selects Amadis , a global payment software editor, to deploy its nexo based payment acceptance application, on an array of traditional payment terminals and Android SoftPOS devices, through a standardized payment acceptance approach, independent of EMV® Level 2 card processing frameworks. This drastically reduces deployment times, maintenance costs, and provides PayPlug with ownership over its card acceptance solutions. The alliance builds on the long-standing partnership between Amadis and PayPlug.
PayPlug’s new application enables every store associate to bring the check out experience to the customer, the POI (point of interaction), wherever the consumer needs it to be, by enabling Android NFC COTS (Commercial-Off-The-Shelf) devices, such as smartphones, tablets or professional dedicated instruments.
“Amadis provided us with an effective way to offer our SME customers with innovative, new ways to accept card-present payments,” said Antoine Grimaud, PayPlug CEO. “We expect the solution to drive new revenue opportunities for our customers, while generating new points of payment acceptance in multiple countries, and enhancing the customer experience.
PayPlug’s new application includes all components of Amadis One (Amadis’ SoftPOS solution), in particular OLA (Open Level 2 API). OLA is an abstraction layer that allows an enterprise to run a payment application with the EMV Level 2 stack of any terminal manufacturer or SoftPOS - allowing enterprises to be fully payment device agnostic, independent of ecosystem, hardware and operating system.
“The new PayPlug application represents a new era for payments acceptance, and we are excited to be a part of their solution,” said Emmanuel Haydont, Amadis CEO. “With nexo protocols a reality for customers, Amadis simplifies nexo deployments and reduces costs, while helping enterprises accelerate deployments and access to multiple countries.”
“We are delighted to see PayPlug, and its customers, become the latest company that will benefit from our standardization work,” explains Jacques Soussana, nexo standards Secretary-General. “Our specifications and protocols remove the barriers traditionally present in the payment acceptance ecosystem, including within non-traditional environments such as mobile acceptance platforms like smartphones, tablets and COTS.”
To make the solution more interoperable, PayPlug’s application needed to effectively integrate with nexo payment standards. Amadis simplified implementation with its open, standards-based off-the-shelf framework that is nexo compliant.
About PayPlug
PayPlug is the French omnichannel pay-by-card solution for SMEs. Since 2012, it has been offering an innovative and easy to use alternative to traditional market players: among other things, the fintech relies on its unique ecosystem of partners and integrated features to simplify all things related to payments for its 15,000 customers, retailers and e-merchants in Europe. After acquiring the status of Payment Institution approved by the ACPR Banque de France, PayPlug joined the BPCE group in April 2017. Over the last three years, PayPlug has experienced nearly 100% growth per year. www.payplug.com
About nexo standards
nexo standards is the association dedicated to removing the barriers present in today’s fragmented global payment acceptance ecosystem. It enables fast, borderless and global payments acceptance by standardizing the exchange of data between all payment acceptance stakeholders. The nexo specifications and messaging protocols adhere to ISO 20022 standards, are universally applicable and fully open. www.nexo-standards.org/
About Amadis
Amadis is a leader in compliant payment software technology, with its software running on more than 40 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment acceptance software technology options based on the most efficient available standards, independent of hardware, retail vertical segment, or geography. The company brings an elite, experienced software team to the industry and enables solutions for international fintech, processors and merchants in over 23 countries. Learn more at www.amadis.ca .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom